SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Anevski Peter

(Last)

(First)

(Middle)

111 EIGHTH AVENUE

(Street)

NEW YORK

10011

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/07/2013

3. Issuer Name and Ticker or Trading Symbol
WebMD Health Corp. [ WBMD ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Exec VP and CFO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	27,296⁽¹⁾	D
Common Stock	202	I	By 401(k) Plan

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	12/10/2018	Common Stock	33,000	$23.61	D
Stock Option (Right to Buy)	⁽³⁾	06/28/2020	Common Stock	25,000	$46.81	D
Stock Option (Right to Buy)	⁽⁴⁾	09/21/2021	Common Stock	32,000	$30	D
Stock Option (Right to Buy)	⁽⁵⁾	05/21/2022	Common Stock	45,000	$22.4	D
Stock Option (Right to Buy)	⁽⁶⁾	11/14/2022	Common Stock	65,000	$13.15	D

Explanation of Responses:

1. Includes 19,000 shares of unvested restricted stock.

2. 33,000 shares are vested and exercisable.

3. 12,500 shares are vested and exercisable, and 6,250 unvested shares are scheduled to vest on each of 6/28/2013 and 6/28/2014.

4. 8,000 shares are vested and exercisable, and 8,000 unvested shares are scheduled to vest on each of 9/21/2013, 9/21/2014 and 9/21/2015.

5. 11,250 unvested shares are scheduled to vest on each of 5/21/13, 5/21/14, 5/21/15 and 5/21/16.

6. 32,500 unvested shares are scheduled to vest on each of 11/14/2013 and 11/14/2014.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Lewis H. Leicher, Attorney-in-Fact for Peter Anevski	05/10/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.